Nasic (Xylometazoline Hydrochloride, Dexpanthenol)

Xylometazoline Hydrochloride and Dexpanthenol, the active ingredients in Nasic, are an alpha‑adrenergic agonist and a provitamin B5 respectively, presented as a nasal spray for nasal use. They treat nasal congestion caused by the common cold, sinusitis and allergic rhinitis in adults and children. GNH USA supplies Nasic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasic works as a topical nasal decongestant that reduces swelling of the nasal mucosa and supports mucosal hydration. - Common cold nasal congestion: relieves blockage and improves breathing. - Sinusitis‑related nasal blockage: decreases swelling and eases sinus drainage. - Allergic rhinitis: reduces obstruction and helps maintain nasal comfort.

Nasic may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal passages - Sneezing or mild itching - Headache - Bitter taste after application - Minor nosebleeds (epistaxis)

Serious or Rare Side Effects: - Severe hypertension or elevated blood pressure - Cardiac arrhythmias - Anaphylactic or severe allergic reactions - Persistent nasal ulceration - Rebound congestion (rhinitis medicamentosa) with prolonged use - Vision changes or ocular pressure increase (rare).

Before using Nasic, consider the following safety measures. - Use in children under 2 years: avoid unless directed by a healthcare professional. - Pregnancy: safety not established; consult a physician before use. - Concurrent nasal decongestants: increased risk of excessive vasoconstriction. - Existing cardiovascular disease: use with caution and monitor blood pressure. - Prolonged use beyond 3‑5 days: risk of rebound congestion; limit duration. - Store at room temperature: keep in original container, protect from moisture and heat.

Nasic can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may potentiate hypertensive effects. - Systemic alpha‑adrenergic agonists (e.g., phenylephrine): additive vasoconstriction risk. - Other nasal decongestants: risk of excessive local vasoconstriction and tissue damage.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible reduction in blood‑pressure‑lowering efficacy. - Corticosteroid nasal sprays: monitor for increased local irritation. - Antihistamines: may enhance sedation if combined with sedating antihistamines.